SCHEMBL3014633

SCHEMBL3014633

Cc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.61
L3MBTL1 Q9Y468 5/20 0.61
ALDH1A1 P00352 5/20 0.61
MAPK1 P28482 4/20 0.59
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
AR P10275 3/20 0.54
MAPT P10636 6/20 0.54
HTT P42858 4/20 0.54
CYP1A2 P05177 3/20 0.54
CYP2C9 P11712 3/20 0.54
CYP2C19 P33261 3/20 0.54
KMT2A Q03164 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
POLB P06746 1/20 0.54
HPGD P15428 1/20 0.54
LMNA P02545 4/20 0.52
CYP3A4 P08684 2/20 0.51
TSHR P16473 1/20 0.48
MCOLN3 Q8TDD5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019911 0.94 SMN1; SMN2 (0.63) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3017457 0.91 SMN1; SMN2 (0.51) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3016724 0.91 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3001913 0.89 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3003995 0.89 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3001102 0.89 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3012975 0.89 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3009419 0.89 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3011753 0.89 KMT2A (0.58) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1
SCHEMBL3000842 0.89 SMN1; SMN2 (0.52) SMN1; SMN2L3MBTL1ALDH1A1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.